Preliminary Study on the Relationship of BRAF Mutations with the Outcome of the First ¹³¹I Radiotherapy and Malignant Biological Characteristics in Papillary Thyroid Carcinoma

References

• Fagin JA, Wells SA Jr. Biologic and clinical perspectives on thyroid cancer. N Engl J Med. 2016;375(11):1054–1067. doi:10.1056/NEJMra1501993
   PubMed Web of Science ®Google Scholar
• Celik M, Bulbul BY, Ayturk S, et al. The relation between BRAFV600E mutation and clinicopathological characteristics of papillary thyroid cancer. Med Glas. 2020;17(1):30–34.
   Google Scholar
• Abdullah MI, Junit SM, Ng KL, Jayapalan JJ, Karikalan B, Hashim OH. Papillary thyroid cancer: genetic alterations and molecular biomarker investigations. Int J Med Sci. 2019;16(3):450–460. doi:10.7150/ijms.29935
   PubMed Web of Science ®Google Scholar
• Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer. 2005;12(2):245–262. doi:10.1677/erc.1.0978
   PubMed Web of Science ®Google Scholar
• Xing M, Alzahrani AS, Carson KA, et al. Association between BRAF V600E mutation and recurrence of papillary thyroid cancer. J Clin Oncol. 2015;33(1):42–50. doi:10.1200/JCO.2014.56.8253
   PubMed Web of Science ®Google Scholar
• Elisei R, Viola D, Torregrossa L, et al. The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study. J Clin Endocrinol Metab. 2012;97(12):4390–4398. doi:10.1210/jc.2012-1775
   PubMed Web of Science ®Google Scholar
• Elisei R, Ugolini C, Viola D, et al. BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study. J Clin Endocrinol Metab. 2008;93(10):3943–3949. doi:10.1210/jc.2008-0607
   PubMed Web of Science ®Google Scholar
• Xing M, Westra WH, Tufano RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab. 2005;90(12):6373–6379. doi:10.1210/jc.2005-0987
   PubMed Web of Science ®Google Scholar
• Sato A, Tanabe M, Tsuboi Y, et al. Circulating tumor DNA harboring the BRAF V600E mutation may predict poor outcomes of primary papillary thyroid cancer patients. Thyroid. 2021. doi:10.1089/thy.2021.0267
   PubMed Web of Science ®Google Scholar
• Enumah S, Fingeret A, Parangi S, Dias-Santagata D, Sadow PM, Lubitz CC. BRAF(V600E) mutation is associated with an increased risk of papillary thyroid cancer recurrence. World J Surg. 2020;44(8):2685–2691. doi:10.1007/s00268-020-05521-2
   PubMed Web of Science ®Google Scholar
• Yao J, Zang W, Ge Y, et al. RAS/BRAF circulating tumor DNA mutations as a predictor of response to first-line chemotherapy in metastatic colorectal cancer patients. Can J Gastroenterol Hepatol. 2018;2018:4248971. doi:10.1155/2018/4248971
   PubMed Web of Science ®Google Scholar
• McCoach CE, Blakely CM, Banks KC, et al. Clinical utility of cell-free DNA for the detection of ALK fusions and genomic mechanisms of ALK inhibitor resistance in non-small cell lung cancer. Clin Cancer Res. 2018;24(12):2758–2770. doi:10.1158/1078-0432.CCR-17-2588
   PubMed Web of Science ®Google Scholar
• Ma F, Zhu W, Guan Y, et al. ctDNA dynamics: a novel indicator to track resistance in metastatic breast cancer treated with anti-HER2 therapy. Oncotarget. 2016;7(40):66020–66031. doi:10.18632/oncotarget.11791
   PubMedGoogle Scholar
• Yong E. Cancer biomarkers: written in blood. Nature. 2014;511(7511):524–526. doi:10.1038/511524a
   PubMed Web of Science ®Google Scholar
• Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6(224):224ra24. doi:10.1126/scitranslmed.3007094
   PubMed Web of Science ®Google Scholar
• Qin Y, Wang JR, Wang Y, et al. Clinical utility of circulating cell-free DNA mutations in anaplastic thyroid carcinoma. Thyroid. 2021;31(8):1235–1243. doi:10.1089/thy.2020.0296
   PubMed Web of Science ®Google Scholar
• Haugen BR, Alexander EK, Bible KC, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1–133.
   PubMed Web of Science ®Google Scholar
• Endocrinology Chinese Society of, Association Endocrine Group of Surgery Branch of Chinese Medical, Association Committee for Head and neck Oncology of Chinese Anti-Cancer, Medicine Chinese Society of Nuclear. Management guidelines for the diagnosis and management of thyroid nodules and differentiated thyroid cancer. Chin J Nucl Med Mol Imaging. 2013;33(2):96–115.
   Google Scholar
• Shen G, Kou Y, Liu B, Huang R, Kuang A. BRAFV600E mutation does not significantly affect the efficacy of radioiodine therapy in patients with papillary thyroid carcinoma without known distant metastases. Clin Nucl Med. 2018;43(7):e215–e219. doi:10.1097/RLU.0000000000002142
   PubMed Web of Science ®Google Scholar
• Liang J, Cai W, Feng D, et al. Genetic landscape of papillary thyroid carcinoma in the Chinese population. J Pathol. 2018;244(2):215–226. doi:10.1002/path.5005
   PubMed Web of Science ®Google Scholar
• Pan W, Zhou L, Ge M, et al. Whole exome sequencing identifies lncRNA GAS8-AS1 and LPAR4 as novel papillary thyroid carcinoma driver alternations. Hum Mol Genet. 2016;25(9):1875–1884. doi:10.1093/hmg/ddw056
   PubMed Web of Science ®Google Scholar
• Pupilli C, Pinzani P, Salvianti F, et al. Circulating BRAFV600E in the diagnosis and follow-up of differentiated papillary thyroid carcinoma. J Clin Endocrinol Metab. 2013;98(8):3359–3365. doi:10.1210/jc.2013-1072
   PubMed Web of Science ®Google Scholar
• Benbassat CA, Mechlis-Frish S, Hirsch D. Clinicopathological characteristics and long-term outcome in patients with distant metastases from differentiated thyroid cancer. World J Surg. 2006;30(6):1088–1095. doi:10.1007/s00268-005-0472-4
   PubMed Web of Science ®Google Scholar
• Bastos AU, Oler G, Nozima BH, Moyses RA, Cerutti JM. BRAF V600E and decreased NIS and TPO expression are associated with aggressiveness of a subgroup of papillary thyroid microcarcinoma. Eur J Endocrinol. 2015;173(4):525–540. doi:10.1530/EJE-15-0254
   PubMed Web of Science ®Google Scholar
• Spitzweg C, Bible KC, Hofbauer LC, Morris JC. Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets. Lancet Diabetes Endocrinol. 2014;2(10):830–842. doi:10.1016/S2213-8587(14)70051-8
   PubMed Web of Science ®Google Scholar
• Chakravarty D, Santos E, Ryder M, et al. Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation. J Clin Invest. 2011;121(12):4700–4711. doi:10.1172/JCI46382
   PubMed Web of Science ®Google Scholar
• Yang K, Wang H, Liang Z, Liang J, Li F, Lin Y. BRAFV600E mutation associated with non- radioiodine-avid status in distant metastatic papillary thyroid carcinoma. Clin Nucl Med. 2014;39(8):675–679.
   PubMed Web of Science ®Google Scholar
• Barbaro D, Incensati RM, Materazzi G, et al. The BRAF V600E mutation in papillary thyroid cancer with positive or suspected pre-surgical cytological finding is not associated with advanced stages or worse prognosis. Endocrine. 2014;45(3):462–468. doi:10.1007/s12020-013-0029-5
   PubMed Web of Science ®Google Scholar
• Tufano RP, Teixeira GV, Bishop J, Carson KA, Xing M. BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. Medicine (Baltimore). 2012;91(5):274–286. doi:10.1097/MD.0b013e31826a9c71
   PubMed Web of Science ®Google Scholar
• Xing M, Liu R, Liu X, et al. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol. 2014;32(25):2718–2726. doi:10.1200/JCO.2014.55.5094
   PubMed Web of Science ®Google Scholar